• Guangzhou Innogen said two third-party contract manufacturing sites for its ecnoglutide alpha injection received PIC/S GMP certificates from Brazil’s ANVISA.
• The certificates follow ANVISA inspections under PIC/S GMP standards, covering drug substance and finished-dose production and quality systems.
• Innogen expects the clearance to support higher commercialization capacity, easing registration and rollout in PIC/S member markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260803-12269446), on August 03, 2026, and is solely responsible for the information contained therein.